Los Angeles-based biopharmaceuticals startup Immix Biopharma said it has filed for an IPO, and has submitted a confidential draft registration statement/S-1 with the Securities and Exchange Commission. Details on that IPO have yet to be announced. Immix Biopharma is developing treatments for cancer. The company's investors include Mesa Verde Ventures. The company said the number of shares to be offered and the price range for the proposed offering have not yet been determined, and the company also did not say which exchange it is currently looking at for its offering.